论文部分内容阅读
目的 探讨多药耐药相关蛋白 (MRP)和P 糖蛋白 (P gp)在甲状腺癌中的表达及临床意义。方法 采用免疫组化SP法回顾性检测分析 80例甲状腺癌组织MRP和P gp表达状况。结果 MRP和P gp表达阳性率分别为 86 .3%、76 .3% ,二者有显著差异 (P <0 .0 5 ) ,两者在甲状腺癌各类型中表达较一致 ,乳头状癌和髓样癌表达阳性率无显著差异 (P >0 .0 5 ) ,滤泡癌中表达阳率明显低于乳头状癌和髓样癌 (P <0 .0 5 )。MRP与P gp共表达率为 76 .3% (6 1/ 80 ) ,具有相关性(P <0 .0 1)。结论 MRP和P gp在甲状腺癌中阳性率较高 ,提示甲状腺癌对化疗有一定多药耐药性。
Objective To investigate the expression and clinical significance of multidrug resistance-related protein (MRP) and P-glycoprotein (P gp) in thyroid cancer. Methods The immunohistochemical SP method was used to detect the expression of MRP and P gp in 80 cases of thyroid carcinoma. Results The positive rates of MRP and P gp expression were 86.3% and 76.3% respectively, which were significantly different between the two groups (P <0.05) The positive rate of medullary carcinoma was no significant difference (P> 0.05), the positive rate of follicular carcinoma was significantly lower than that of papillary carcinoma and medullary carcinoma (P <0.05). The co-expression rate of MRP and P gp was 76.3% (6 1/80), with correlation (P <0.01). Conclusion The positive rate of MRP and P gp in thyroid cancer is high, suggesting that thyroid cancer has some multidrug resistance to chemotherapy.